Results 71 to 80 of about 12,926,306 (256)
Anti-PD-1 and anti-CTLA-4 treatment of iAST tumors.
, 2019 A, Treatment schedule: anti-PD-1 (10 mg/kg, i.p.) and anti-CTLA-4 (5 mg/kg, i.p.) therapy started at day 53 after virus injection and was applied in three doses at days 0, 3, and 7.
Veronika Schandl (6941093) +10 more
core +1 more source
Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma
Advanced Science, EarlyView.This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert +8 more
wiley +1 more source
, 2017 Background: Anti-glutamic acid decarboxylase antibodies are associated with encephalopathy, an autoimmune central nervous system inflammatory disease. The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)+49 A/G polymorphism has been shown to confer ...
Lin, Jainn-Jim;Lin, Kuang-Lin;Wang, Yu;Wang, Huei-Shyong;Hsia, Shao-Hsuan;Chang, Luan-Yin +1 more
core +1 more source
Advanced Science, EarlyView.BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai +7 more
wiley +1 more source
Cellular Physiology and Biochemistry, 2018 Background/Aims: Gastric cancer (GC) is one of the most common and lethal varieties of cancers. Anticancer activities of anti-CTLA-4 and anti-PD-1 antibodies have been explored in different cancers, including GC.
Bin Wang, Lei Qin, Mei Ren, Hao Sun
doaj +1 more source
CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. [PDF]
PLoS ONE, 2008 The balance of T-cell proliferation, anergy and apoptosis is central to immune function. In this regard, co-receptor CTLA-4 is needed for the induction of anergy and tolerance. One central question concerns the mechanism by which CTLA-4 can induce T-cell
Helga Schneider +3 more
doaj +1 more source
Advanced Science, EarlyView.A hierarchically selective immunotherapeutic nanoplatform, mGls@HEV‐MTP, selectively restores macrophage immunocompetence through GLS1‐mediated restoration of glutaminolysis‐fueled anaplerosis. Concurrently, it renders Staphylococcus aureus (S. aureus) more readily recognizable to the metabolically reprogrammed macrophages, thereby facilitating ...
Weinan Yang +17 more
wiley +1 more source
Frontiers in EndocrinologyObjectiveImmune checkpoint inhibitors (ICIs) are revolutionary in oncology but may cause immune-related (IR) side effects, such as hypophysitis. Treatment with anti-PD-(L)1, anti-CTLA-4 or anti-CLTA-4/PD-1 may induce hypophysitis, but little is known ...
Stephanie van der Leij +9 more
doaj +1 more source
The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
BMC Biology, 2020 Background Immune checkpoint inhibitor (ICPI) can augment the anti-tumour response by blocking negative immunoregulators with monoclonal antibodies. The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody is the first ICPI which has shown ...
Shashuang Zhang +4 more
doaj +1 more source
Reciprocal Dosing of Anti-PD-1 and Anti-CTLA-4 Antibodies in a Staged MC38 Tumor Model.
, 2016 Reciprocal Dosing of Anti-PD-1 and Anti-CTLA-4 Antibodies in a Staged MC38 Tumor Model.
Mark J. Selby (3110964) +13 more
core +1 more source